Ozagrel

Ozagrel is a prescribed medication, commonly known as Ticlopidine HCl, that belongs to a category of drugs called antiplatelet agents. Platelets are small blood cells necessary for clotting, crucial in stopping bleeding. However, a build-up of platelet plugs in the blood vessels can lead to narrowing and cause cardiovascular and cerebrovascular diseases including heart attack, stroke, and severe chest pain. Ozagrel prevents the formation of these undesired clots by slowing down platelet aggregation without significantly affecting the usual blood clotting mechanism.
Physicians generally prescribe Ozagrel in combination with aspirin for the prevention of stroke and disabling ischemic events mainly in patients who have just undergone a procedure termed percutaneous coronary intervention (PCI) to treat narrowed vessels in the heart. The medication proves effective in lowering the risk associated with arterial blood flow blockages and reducing severe complications in these scenarios.
Although Ozagrel has been proven significantly effective in managing the above problems, it comes with potential serious side effects including diarrhoea, thrombotic thrombocytopenic purpura (TTP, which is a rare but serious form of anaemia), or even fatal hepatoxicity (liver damage). Therefore, patient safety and careful monitoring after the commencement of Ozagrel therapy is a critical aspect during its usage.
Only a qualified healthcare professional can determine when Ozagrel is advisable and at what doses. The prescription is based upon the patient’s overall health picture, considering the potential benefits the drug could offer against potential risks and side effects.